Discovery - University of Dundee - Online Publications

Library & Learning Centre

Long-acting β-agonist prescribing in people with asthma in primary care

Long-acting β-agonist prescribing in people with asthma in primary care

Research output: Contribution to journalArticle

View graph of relations

Authors

Research units

Info

Original languageEnglish
Pages (from-to)192-194
Number of pages3
JournalThorax
Volume68
Issue number2
DOIs
StatePublished - 1 Feb 2013

Abstract

Long-acting ß2-agonist (LABA) monotherapy is contraindicated in asthma following reports of serious adverse events. Anonymised Scottish health data were used to determine the prevalence of LABA prescribing and LABA monotherapy (sustained and episodic) in asthma during 2006. Of 73 486 asthma patients identified, 5592 (7.6%; 95% CI 7.4% to 7.8%) were prescribed LABAs as a separate inhaler of which 991 patients had LABA monotherapy (17.7% (95% CI 16.7% to 18.7%) of patients at risk). Asthma reviews were associated with reductions in sustained (OR 0.44; 95% CI 0.32 to 0.61) but not episodic monotherapy (OR 1.16; 95% CI 0.85 to 1.57). These findings support recent changes in UK asthma guidelines recommending LABAs in fixed-dose combination inhalers.

Documents

DOI

Library & Learning Centre

Contact | Accessibility | Policy